Compare with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES ABBOTT INDIA ALKEM LABORATORIES/
ABBOTT INDIA
 
P/E (TTM) x 22.4 48.2 46.5% View Chart
P/BV x 5.4 15.6 34.7% View Chart
Dividend Yield % 0.9 0.4 203.5%  

Financials

 ALKEM LABORATORIES   ABBOTT INDIA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
ABBOTT INDIA
Mar-19
ALKEM LABORATORIES/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs2,7208,834 30.8%   
Low Rs1,6605,458 30.4%   
Sales per share (Unadj.) Rs697.91,731.1 40.3%  
Earnings per share (Unadj.) Rs96.1211.9 45.4%  
Cash flow per share (Unadj.) Rs117.3219.9 53.3%  
Dividends per share (Unadj.) Rs25.0065.00 38.5%  
Dividend yield (eoy) %1.10.9 125.5%  
Book value per share (Unadj.) Rs515.2945.2 54.5%  
Shares outstanding (eoy) m119.5721.25 562.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.14.1 76.0%   
Avg P/E ratio x22.833.7 67.6%  
P/CF ratio (eoy) x18.732.5 57.5%  
Price / Book Value ratio x4.37.6 56.2%  
Dividend payout %26.030.7 84.8%   
Avg Mkt Cap Rs m261,879151,848 172.5%   
No. of employees `00014.33.5 411.2%   
Total wages/salary Rs m15,0554,356 345.6%   
Avg. sales/employee Rs Th5,822.610,555.5 55.2%   
Avg. wages/employee Rs Th1,050.51,249.9 84.0%   
Avg. net profit/employee Rs Th802.01,292.2 62.1%   
INCOME DATA
Net Sales Rs m83,44436,786 226.8%  
Other income Rs m1,0421,133 92.0%   
Total revenues Rs m84,48637,919 222.8%   
Gross profit Rs m14,7346,047 243.6%  
Depreciation Rs m2,528169 1,493.9%   
Interest Rs m65123 2,891.6%   
Profit before tax Rs m12,5986,989 180.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,1052,485 44.5%   
Profit after tax Rs m11,4934,503 255.2%  
Gross profit margin %17.716.4 107.4%  
Effective tax rate %8.835.6 24.7%   
Net profit margin %13.812.2 112.5%  
BALANCE SHEET DATA
Current assets Rs m54,96027,610 199.1%   
Current liabilities Rs m32,4338,569 378.5%   
Net working cap to sales %27.051.8 52.2%  
Current ratio x1.73.2 52.6%  
Inventory Days Days8060 132.1%  
Debtors Days Days7227 263.3%  
Net fixed assets Rs m32,7101,057 3,094.9%   
Share capital Rs m239213 112.5%   
"Free" reserves Rs m61,36819,873 308.8%   
Net worth Rs m61,60720,086 306.7%   
Long term debt Rs m1,5920-   
Total assets Rs m99,43329,409 338.1%  
Interest coverage x20.4311.6 6.5%   
Debt to equity ratio x00-  
Sales to assets ratio x0.81.3 67.1%   
Return on assets %12.215.4 79.4%  
Return on equity %18.722.4 83.2%  
Return on capital %21.034.9 60.1%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,061369 4,353.1%   
Fx outflow Rs m2,4834,918 50.5%   
Net fx Rs m13,578-4,549 -298.5%   
CASH FLOW
From Operations Rs m5,8514,991 117.2%  
From Investments Rs m-7,414-2,570 288.5%  
From Financial Activity Rs m792-1,428 -55.4%  
Net Cashflow Rs m-731993 -73.6%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 33.1 7.9 419.0%  
FIIs % 0.0 0.1 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 17.1 -  
Shareholders   68,381 18,270 374.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   WOCKHARDT  TTK HEALTHCARE  SHASUN PHARMA  BIOCON   FULFORD INDIA  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 200 Points Higher; Dow Futures Up by 37 Points(12:30 pm)

Share markets in India are presently trading marginally higher. The BSE Sensex is trading up by 214 points, up 0.4% at 50,619 levels.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY21); Net Profit Down 5.1% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Mar 8, 2021 03:00 PM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - TORRENT PHARMA COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS